Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

MoMa Signature During Granulomatosis

Role of Monocytes (Mo) and Macrophages (Ma) in Sarcoidosis and in Tuberculosis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Sarcoidosis is a systemic inflammatory disease characterized by unspecific granuloma formation. Our hypothesis is that granuloma formation and maintenance mainly relies on the overactivation of monocytes (Mo) and macrophages (Ma). To this end, the study aims (i) to define MoMa systemic signature in sarcoidosis, (ii) to characterize this signature in situ on tissue samples, and (iii) to identify causative factors that participate to the MoMa chronic overactivation. Thus, a cohort of sarcoidosis patients will be compared with tuberculosis patients. The MoMa systemic signature will be defined on whole blood (TruCulture model) and then in situ through different methods (multi-parameter spectral flow cytometry, RNA-seq, Luminex, imaging mass cytometry). The epigenome of monocytes will be studied thanks to CUT\&Tag. The MoMa systemic signature will be defined ex vivo at different time points during the course of the disease with phenotypic, transcriptomic, cytokine and functional approaches. The previously identified signature will be studied in situ and completed by the characterization of granuloma architecture and microenvironmental interactions, which could be modulated by epigenetic modifications. Hence, the epigenome of monocytes will be analyzed in two groups (sarcoidosis and tuberculosis). These results would allow to better understand sarcoidosis physiopathology and, in fine, may raise new therapeutic strategies. Finally, the study could challenge the dogma on innate immunity/auto-inflammation versus adaptive immunity/auto-immunity/memory.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Male and female \> 18 years old 2. Diagnosis of sarcoidosis and of tuberculosis 3. Affiliated to medical insurance Who Should NOT Join This Trial: 1. HIV infection 2. pregnant or breastfeeding woman 3. Patient under legal protection, guardianship or curators 4. Absence of signed consent" Secondary exclusion criteria Other causes of granulomatosis ultimately identified as sarcoidosis or tuberculosis Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria: 1. Male and female \> 18 years old 2. Diagnosis of sarcoidosis and of tuberculosis 3. Affiliated to medical insurance Exclusion criteria: 1. HIV infection 2. pregnant or breastfeeding woman 3. Patient under legal protection, guardianship or curators 4. Absence of signed consent" Secondary exclusion criteria Other causes of granulomatosis ultimately identified as sarcoidosis or tuberculosis

Treatments Being Tested

OTHER

blood sample

blood sample collection

Locations (1)

Hôpital Bichat
Paris, France